BofA Securities on Chemed (CHE): 'attractive growth at Vitas (high single digits census) and stabilization at Roto'

BofA Securities analyst Joanna Gajuk reiterated a Buy rating and $708.00 price target on Chemed (NYSE: CHE).

The analyst comments "We hosted a fireside chat with Chemed’s (CHE) leadership team including Kevin McNamara, President & CEO, Nick Westfall, CEO of Vitas, and Mike Witzeman, CFO, at the BofA Health Care Conference. The company is proactively managing the Medicare cap situation, noting it is confident it can manage through that while not impacting the core growth. We maintain our Buy rating given the attractive growth at Vitas (high single digits census) and stabilization at Roto."

For an analyst ratings summary and ratings history on Chemed click here. For more ratings news on Chemed click here.

Shares of Chemed closed at $557.17 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Cosa Resources announces C$5 million bought deal private placement
• Bitmine Immersion Technologies plans $300 million preferred stock offering